Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia

Read also

ESMO 2025

ESMO 2025 – Merck shoots for an ovarian cancer first

Clarametyx

Clarametyx completes enrolment in cystic fibrosis trial

Pelage Pharmaceuticals’ alopecia

Pelage Pharmaceuticals’ alopecia treatment moves forward to phase 3 trial

J&J’s Tecvayli-Darzalex

J&J’s Tecvayli-Darzalex  trumps SoC in multiple myeloma